BRAF and melanoma: Furthermore, in the last years, the identification of, somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas has resulted in an opportunity to test oncogene-targeted therapy for this disease.